title: Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
abstract: The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA). Preirradiation temozolomide (150 mg/m(2)/day) was given on a 7-day-on/7-day-off schedule for up to six cycles. The primary end point was the response rate during the 6-month, pre-RT chemotherapy. Tumor tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation. Forty-two patients were enrolled; 39 were eligible. The objective response rate was 32% (6% [complete response, CR], 26% [partial response PR]), and the rate of progression during pre-RT chemotherapy was 10%. The worst nonhematological toxicity was grade 4 in three patients (8%). Twenty-two patients completed concurrent chemotherapy and RT. There were no grade 4 nonhematological toxicities during the concurrent chemotherapy and RT. Seventeen of 28 (60.7%) evaluable cases had codeletion of 1p/19q; all 17 were free from progression at 6 months. Sixteen of 20 (80%) evaluable cases had MGMT-promoter methylation; all 16 were free from progression at 6 months. In conclusion, the rate of progression of 10% during pre-RT temozolomide chemotherapy for newly diagnosed AO and MAO compared favorably with prior experience with pre-RT PCV chemotherapy (20% in RTOG 9402). The toxicity of the dose-intense pre-RT regimen used in this study may warrant evaluation of other, less intense dosing strategies. Future studies will need to prospectively stratify patients according to the presence of deletions of chromosomes 1p and 19q.
authors.affiliation: Cleveland Clinic, Brain Tumor and NeuroOncology Center, Cleveland, OH 44195, USA. vogelbm@ccf.org
authors.forename: Michael A
authors.initials: MA
authors.lastname: Vogelbaum
authors.forename: Brian
authors.initials: B
authors.lastname: Berkey
authors.forename: David
authors.initials: D
authors.lastname: Peereboom
authors.forename: David
authors.initials: D
authors.lastname: Macdonald
authors.forename: Caterina
authors.initials: C
authors.lastname: Giannini
authors.forename: John H
authors.initials: JH
authors.lastname: Suh
authors.forename: Robert
authors.initials: R
authors.lastname: Jenkins
authors.forename: James
authors.initials: J
authors.lastname: Herman
authors.forename: Paul
authors.initials: P
authors.lastname: Brown
authors.forename: Deborah T
authors.initials: DT
authors.lastname: Blumenthal
authors.forename: Christopher
authors.initials: C
authors.lastname: Biggs
authors.forename: Christopher
authors.initials: C
authors.lastname: Schultz
authors.forename: Minesh
authors.initials: M
authors.lastname: Mehta
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001254:Astrocytoma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics; D003131:Combined Modality Therapy; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000235:genetics; D045643:DNA Repair Enzymes / Q000235:genetics; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000628:therapy*; D009837:Oligodendroglioma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011379:Prognosis; D011401:Promoter Regions, Genetic; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000235:genetics; D055815:Young Adult
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide
references.citation: Neuro Oncol. 2007 Jul;9(3):314-8
references.pmid: 17435180
references.citation: J Neurosurg. 1985 Dec;63(6):881-9
references.pmid: 4056902
references.citation: J Clin Oncol. 1994 Oct;12(10):2013-21
references.pmid: 7931469
references.citation: J Neurooncol. 2003 Feb;61(3):267-73
references.pmid: 12675321
references.citation: Cancer Treat Rev. 1997 Jan;23(1):35-61
references.pmid: 9189180
references.citation: J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
references.pmid: 9776413
references.citation: Neurology. 2001 Jul 24;57(2):340-2
references.pmid: 11468326
references.citation: Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30
references.pmid: 11020580
references.citation: J Clin Oncol. 1990 Jul;8(7):1277-80
references.pmid: 2358840
references.citation: Cancer Res. 2001 Jun 15;61(12):4689-92
references.pmid: 11406538
references.citation: Oncogene. 1999 Jul 15;18(28):4144-52
references.pmid: 10435596
references.citation: Cancer Chemother Rep. 1966 Mar;50(3):163-70
references.pmid: 5910392
references.citation: Lancet Oncol. 2001 Sep;2(9):552-60
references.pmid: 11905710
references.citation: J Neurooncol. 2003 Sep;64(3):271-8
references.pmid: 14558604
references.citation: J Clin Oncol. 2001 May 1;19(9):2449-55
references.pmid: 11331324
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2715-22
references.pmid: 16782911
references.citation: Clin Cancer Res. 2001 Apr;7(4):839-45
references.pmid: 11309331
references.citation: Br J Cancer. 2000 Sep;83(5):588-93
references.pmid: 10944597
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Cancer Res. 1998 Oct 1;58(19):4363-7
references.pmid: 9766665
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2707-14
references.pmid: 16782910
references.citation: J Neurosurg. 1996 Oct;85(4):602-7
references.pmid: 8814163
references.citation: J Clin Oncol. 2000 Feb;18(3):636-45
references.pmid: 10653879
references.citation: Cancer Res. 2006 Oct 15;66(20):9852-61
references.pmid: 17047046
references.citation: J Clin Oncol. 2003 Jul 1;21(13):2525-8
references.pmid: 12829671